Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DNDN 19.48
RTP up another $7
CROX.....who could ever guess those things would sell the way they have?????? Only in America I guess, come up with an idea then get a great marketing plan and people will pay!!!!!!!!
NUVO, CEGE ticking up....probably piggy backing DNDN
YHOO 22 million WWWWWOOOOOOWWWWWW
DNDN looking pretty strong here 19.30 x 19.32.....IMHO
Icon....ZOLT news.....
Zoltek Reports Continued Acceleration of Growth Trends in Second Quarter
ST. LOUIS, May 3 /PRNewswire-FirstCall/ -- Zoltek Companies, Inc. (Nasdaq: ZOLT) today reported continued strong gains in sales and results of operations for the second quarter of its 2007 fiscal year.
For the quarter ended March 31, 2007, Zoltek's net sales grew to $36.7 million, compared to $26.2 million in the second quarter of fiscal 2006, an increase of 40%. Operating income from continuing operations increased to $5.9 million, compared to $3.1 million in the previous year's second quarter, an increase of 87%. Similarly, Zoltek reported a positive cash flow from operating activities of $3.5 million for the quarter, compared to $0.6 million in the previous year's quarter. On a sequential quarter basis compared to the first quarter of the current fiscal year, Zoltek's net sales increased 21.5%.
For the six months ended March 31, 2007, Zoltek's net sales increased 60.5% to $67.0 million from $41.8 million in the first six months of fiscal 2006. Zoltek reported operating income from continuing operations of $8.1 million in the first half of fiscal 2007, compared to $1.4 million in the first half of fiscal 2006.
'We are very pleased that our results continue to show strong growth trends,' Zsolt Rumy, Zoltek's Chairman and Chief Executive Officer, said. 'We are on target in meeting our goals for sales growth and profitability improvements. We have raised our gross margin over the past year to 29% from 23% due to successful implementation of recent price increases and our focus on execution of productivity improvements. Our strong performance over the first half of the year reflects the contribution of two carbon fiber production lines that commenced operation in January, and continued strong demand for our carbon fibers from the wind energy and other sectors. With the addition of two more carbon fiber production lines that have just been placed in service at our facilities in Hungary, we expect to maintain accelerating sales and improved operating results through the remainder of fiscal 2007.'
The company's expansion program continues in Hungary according to plan. In addition, plans are being prepared to install the basic polymerization and infrastructure for a new precursor facility to increase the precursor capacity to support future aggressive carbon fiber growth.
The financial report for the quarter included a $5.3 million non-cash
charge related to conversion of convertible debt issued by the company in
prior years. This charge does not reflect on the operating performance of
Zoltek's business.
Three Months Ended Three Months Ended
March 31, December 31,
(in $ millions, except 2007 2006 2006
per share data)
Sales $36.7 $26.1 $30.2
Gross margin $10.6~29% $7.2~27% $7.8~26%
Operating income from
continuing operations* $5.9~16% $3.1~12% $3.0~10%
Cash provided by operating
activities $3.5 $0.6 $3.5
* Non-U.S. GAAP measures. See attached Summary Financial Results for
reconciliation.
Zoltek will host a conference call to review second quarter 2007 results and answer questions on Friday, May 4, 2007, at 10:00 am CT. The conference dial-in number is (800) 378-6592. The confirmation code is 5544971. Individuals who wish to participate should dial in 5 to 10 minutes prior to the scheduled start time.
This press release contains forward-looking statements, which are based upon the current expectations of the Company. Because these forward-looking statements are inherently subject to risks and uncertainties, there are a number of factors that could cause the Company's plans, actions and actual results to differ materially. Among these factors are the Company's ability to: successfully resolve pending litigation; re-activate its formerly idle manufacturing facilities on a timely and cost-effective basis, meet current order levels for carbon fibers; successfully add new capacity for the production of carbon fiber and precursor raw material; execute plans to exit its specialty products business and reduce costs; achieve profitable operations; raise new capital and increase its borrowing at acceptable costs; manage changes in customers' forecasted requirements for the Company's products; continue investing in application and market development; manufacture low-cost carbon fibers and profitably market them; and penetrate existing, identified and emerging markets. The timing and occurrence (or non-occurrence) of transactions and events that determine the future effect of these factors on the Company, as well as other factors, may be beyond the control of the Company. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
ZOLTEK COMPANIES, INC.
SUMMARY FINANCIAL RESULTS
(Amounts In Thousands Except Per Share Data)
(Unaudited)
Three Months Ended
March 31 March 31 December 31
2007 2006 2006
Net sales $ 36,742 $26,198 $ 30,285
Cost of sales 26,154 18,923 22,434
Application and
development costs 1,820 1,290 1,592
Selling, general and
administrative expenses 2,910 2,853 3,242
Operating income from
continuing operations* 5,858 3,132 3,017
Interest income 268 - 386
Net interest expense
related to non-convertible
debt* (84) (92) (71)
Other, net (467) (150) (274)
Income tax expense 292 181 203
Income from continuing
operations before
convertible debt expense* 5,283 2,709 2,855
Expense related to
convertible debt
and warrant issuances* (5,340) (30,484) (8,450)
Loss from continuing
operations (57) (27,775) (5,595)
Income (loss) on
discontinued operations,
net of taxes 51 42 (68)
Net loss (6) (27,733) (5,663)
Diluted loss per share:
Continuing operations $(0.00) $(1.31) $(0.23)
Discontinued operations - - (0.00)
Total $(0.00) $(1.31) $(0.23)
Weighted average common
shares outstanding - diluted 27,650 21,147 25,961
* To provide transparency about measures of the Company's financial
performance which management considers most relevant, we supplement the
reporting of Zoltek's consolidated financial information under GAAP with
'income from continuing operations before convertible debt expense'
which is a non-GAAP financial measure. These non-GAAP financial measures
should be considered in addition to, and not as a substitute or superior
to, the other measures of financial performance prepared in accordance
with GAAP. Using only the non-GAAP financial measures to analyze our
performance would have material limitations because its calculation is
based on the subjective determination of management regarding the nature
and classification of events and circumstances that investors may find
material. Management compensates for these limitations by utilizing both
the GAAP and non-GAAP measures of its business. Zoltek believes the
presentation of these measures is useful to investors because they are
more indicative of the Company's underlying business performance and,
since the Company no longer has outstanding any convertible debt or
warrants that require derivative accounting.
ZOLTEK COMPANIES, INC.
SUMMARY FINANCIAL RESULTS
(Amounts In Thousands Except Per Share Data)
(Unaudited)
Six Months Ended
March 31 March 31
2007 2006
Net sales $67,027 $41,755
Cost of sales 48,588 31,950
Application and development costs 3,412 2,368
Selling, general and administrative expenses 6,152 5,319
Operating income from continuing operations* 8,875 2,118
Interest income 654 -
Net interest expense related to
non-convertible debt* (155) (265)
Other, net (741) (155)
Income tax expense 495 278
Income from continuing operations before
convertible debt expense* 8,138 1,420
Expense related to convertible
debt and warrant issuances* (13,790) (23,067)
Loss from continuing operations (5,652) (21,647)
Income (loss) on discontinued
operations, net of taxes (17) 202
Net loss (5,669) (21,445)
Diluted loss per share:
Continuing operations $(0.21) $(1.05)
Discontinued operations - 0.01
Total $(0.21) $(1.04)
Weighted average common shares
outstanding - diluted 26,613 20,526
* To provide transparency about measures of the Company's financial
performance which management considers most relevant, we supplement the
reporting of Zoltek's consolidated financial information under GAAP with
'income from continuing operations before convertible debt expense'
which is a non-GAAP financial measure. These non-GAAP financial measures
should be considered in addition to, and not as a substitute or superior
to, the other measures of financial performance prepared in accordance
with GAAP. Using only the non-GAAP financial measures to analyze our
performance would have material limitations because its calculation is
based on the subjective determination of management regarding the nature
and classification of events and circumstances that investors may find
material. Management compensates for these limitations by utilizing both
the GAAP and non-GAAP measures of its business. Zoltek believes the
presentation of these measures is useful to investors because they are
more indicative of the Company's underlying business performance and,
since the Company no longer has outstanding any convertible debt or
warrants that require derivative accounting.
SOURCE Zoltek Companies, Inc.
Source: PR Newswire (May 3, 2007 - 8:38 PM EDT)
News by QuoteMedia
www.quotemedia.com
LVLT...continues its climb......slowly
hussler.....would never happen!!!!IMHO
ZOLT bidding up $4-5 pre-market....wow
looks like a bad day in SHLD land
YHOO 9 million and counting
7 MILLION DONE ALREADY
DNDN....19.25 X 19.36
Yahoo! (YHOO - Cramer's Take - Stockpickr - Rating) surged 14% early Friday on news reports that a deal with Microsoft (MSFT - Cramer's Take - Stockpickr - Rating) may be in the offing.
The New York Post says Microsoft asked the Sunnyvale, Calif.-based Net giant to enter formal talks. Citing Wall Street sources, the Post put a $50 billion price tag on the deal.
The Post said Microsoft has been driven to the talks by its failure to buy ad server DoubleClick, which went to Google (GOOG - Cramer's Take - Stockpickr - Rating).
Shares of Yahoo! rose $4.08 early Friday to $32.26.
YHOO looks like a crazy day......Can Mr. Softy really buy them?????
Madcow....that was a before picture....i fed her and now this......http://flashgamesite.com/funnyflashmovie616.html
DNDN chewing through the 18.40's.....watching the tape on this one is like watching the dot coms in there hey day.....never boring.
Taken pictures of my wife again MAD???? LOL
Gotta love GS slow and steady.
DNDN shorts soiling their shorts
DNDN....maybe he was right!!!!!!!!!!
DNDN....lets see if this guy is right....I guess if it keeps happening around same time could signal fundies taking positions.....IMHO
Posted by: GreedyFox2
In reply to: GreedyFox2 who wrote msg# 179212 Date:5/3/2007 12:00:12 PM
Post #of 179245
DNDN 2:00 is the hour she runs. look at the chart & see the trend this week.. 2:00 EST should be (( kaboomage ))
No prob Fastlizzy.....Making me think twice about holding a whole position into May 15th!!!!!!!!!!!
LVLT bounced off that 5.22 of level moving up 5.63
GERN up again today
Mr. Softie continues twords its 52 week high.
FCEL getting knocked down a little further today
Barb....This is just one place.....http://finance.yahoo.com/q/ks?s=DNDN
go to share statistics section on this page.
MAD....ROFLMAO
INSM here is the other News 4/30/07
Insmed Releases Positive Results from IPLEX Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
Apr 30, 2007 09:00:43 (ET)
RICHMOND, Va., Apr 30, 2007 (BUSINESS WIRE) -- Insmed Inc., (INSM, Trade ) today announced positive results from a Phase II investigator-sponsored clinical study of the company's drug IPLEX(TM) in HIV-infected patients affected with HIV-associated Adipose Redistribution Syndrome (HARS).
Preliminary results from the study, being conducted at the University of California, San Francisco, showed that three months of 0.5 mg/kg/day IPLEX treatment in seven patients increased IGF-I levels 3-fold and was associated with significant improvements in fasting glucose levels, the amount of insulin secreted during an oral glucose tolerance test, and overall insulin sensitivity. Moreover, there was a significant reduction in trunk fat and a positive downward trend in waist circumference when compared to baseline. Lipid profiles also tended to improve.
Notably, normal glucose tolerance was restored in half of the six patients diagnosed with impaired glucose tolerance (IGT) at the start of the study. These IGT patients also experienced a significant decrease in visceral adipose tissue (VAT). Impaired glucose tolerance is characterized by blood glucose between 140 and 200 mg/dl at the 120-minute measurement of an oral glucose tolerance test. The next phase of the study is underway to explore an IPLEX dose of 1.0 mg/kg/day given for six months.
"Our study has demonstrated that a low dose of IPLEX increased IGF-I levels 3-fold and positively impacted abnormal glucose metabolism, dyslipdemia and abnormal fat distribution, which are present in a significant number of HIV patients treated with highly active antiretroviral therapy (HAART)," said Morris Schambelan, M.D., the study's principal investigator and professor of medicine and director of the General Clinical Research Centers at University of California, San Francisco, and chief of endocrinology at San Francisco General Hospital.
"We are very encouraged by these preliminary results with low-dose IPLEX. We believe a product that improves fat distribution while also improving insulin sensitivity would be a valuable therapy for this patient population, and the positive effects on insulin sensitivity observed in this study are consistent with what we observed in our previous studies with IPLEX in patients with diabetes. These results support the most important differentiating property of our product in this patient population, which is IPLEX's ability to improve glucose homeostasis. Competitor products such as TH9507 and growth hormone reportedly either do not alter glucose homeostasis or exacerbate it, respectively. When considering that up to 40% of this population has impaired glucose homeostasis, then this property of IPLEX becomes even more valuable," said Dr. Geoffrey Allan, president and Chief Executive Officer of Insmed.
Study Description
The ongoing, open-label, investigator-sponsored Phase II clinical study is designed to evaluate the safety and efficacy of IPLEX in two cohorts of subjects, the first of which received a 0.5 mg/kg/day dose and the second of which will receive 1.0 mg/kg/day dose. The primary endpoints of the study are to determine the safety and tolerability of IPLEX and its effects on visceral fat and insulin sensitivity.
About HARS
An estimated 80,000 HIV patients in the U.S. have HARS, according to published reports. This disorder is marked by abnormal metabolism, including central fat accumulation (visceral adiposity and buffalo hump) with or without fat loss in the limbs. These features have increased markedly with the advent of highly active antiretroviral therapy (HAART) for HIV. Recent studies performed in subjects on HAART suggest nearly 40% of individuals develop the morphologic features characteristic of this syndrome.
About IPLEX
IPLEX was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency (Primary IGFD). IPLEX (rhIGF-I/rhIGFBP-3) is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug is also being investigated for various other indications with unmet medical needs, including myotonic muscular dystrophy, retinopathy of prematurity and amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease).
About the University of California, San Francisco
The University of California, San Francisco (UCSF), is a leading university that consistently defines health care worldwide by conducting advanced biomedical research and providing leading life science education and complex patient care. For more information, please visit www.ucsf.com .
About Insmed
Insmed is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com .
Forward-Looking Statements
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding planned clinical study design, our regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the company may lack financial resources to complete development of product candidates, the FDA may interpret the results of our studies differently than we have, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release.
SOURCE: Insmed Inc.
Investor Relations International
Haris Tajyar, 818-382-9702
htajyar@irintl.com
Sweet they had other positive news on another Phase II study a few days ago.
INSM 125k just ran through in 10 seconds +10-15% pre market
INSM GOING BONKERS RIGHT NOW!!!!!!!!!!!
DNDN ticking up yet again Pre-market
Stem cells doing well ASTM, GERN, ...
Icon very good points.
saw it on another board and figured id share.....I guess they probably need billing codes ahead of time before the drugs are approved??????
MSFT less then $1 from 52 week high